2023 Full-year results
Wesfarmers Health performance summary
Year ended 30 June 1,2 ($m)
Revenue
2023
2022
5,312
1,240
EBITDA³
Depreciation and amortisation
EBIT3,4
Interest on lease liabilities
EBT3,4
124
(2)
(74)
(22)
50
(24)
(5)
(1)
45
(25)
EBT³ (excluding purchase price allocation adjustments)
58
(14)
EBT margin (%) (including purchase price allocation adjustments)
0.8
n.m.
ROC (R12, %)
4.2
n.r.
Safety (R12, TRIFR)
6.6
n.r.
Scope 1 and 2 market-based emissions 5 (ktCO2e)
11.6
13.8
1. Refer to slide 64 for relevant definitions.
2. 2022 includes API's results from 31 March 2022 to 30 June 2022.
3. 2022 includes impairments of $21m relating to Priceline company-owned stores, and other non-recurring expenses of $4m relating to the exit from the Consumer Brands
manufacturing operations in New Zealand.
4. 2023 includes $13m and 2022 includes $11m of non-cash expenses relating to assets recognised as part of the acquisition of API.
5. 2022 full-year emissions estimated for comparison purposes.
2023 Full-year results | 48View entire presentation